Your English writing platform
Discover LudwigExact(1)
In analogy to the ACCOMPLISH trial, 60 the COLM (Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients) study compares combination therapy using an ARB (olmesartan) and a CCB with the combination of an ARB and a diuretic in high-risk elderly (65 84 years) hypertensive patients.
Similar(58)
The analysis compares combinations of programs targeting adolescents, parents of newborns (i.e. cocoon strategy), or adults of various ages.
However, where directly compared, combination therapy usually provides an advantage over monotherapy.
This study retrospectively compared combination corticosteroid and cyclophosphamide therapy in a large population of patients who meet the current consensus definition of IPF.
ORs comparing combination therapy with ARB along with ACEi versus ACEi was 1.01 (95% CI 0.94-1.10), combination versus ARB alone 1.02 (95% CI 0.91-1.13), alonelone versus ACEi alone 1.06 (95% CI 0.97-1.16) ARB ARB versus placebo/control without ACEi 0.97 (95% CI 0.91-1.04).
Our study is based on trials retrieved from an extensive literature search to identify all relevant eligible trials comparing combination of ARB plus ACE inhibitor therapy to ACE inhibitor therapy alone in patients with congestive heart failure.
One model [ 35] compared combination therapy with antidepressant therapy alone.
Several small trials compared combination prophylaxis with fluoroquinolone prophylaxis alone.
162 This meta-analysis included seven trials comparing combination therapy with VBL and three trials comparing combination therapy with drug treatment.
Since then various RCT have been published comparing combination therapy with interferon monotherapy [ 6- 9].
Randomized trials comparing combination therapies of bendamustine and rituximab and pentostatin and rituximab are ongoing.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com